Travere Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $490.7 | $233.2 | $145.2 | $109.5 | $131.8 |
| Operating income | -$62.8 | -$323.8 | -$388.1 | -$319.8 | -$199.4 |
| Net income | -$25.5 | -$321.5 | -$111.4 | -$278.5 | -$180.1 |
| Cash Flow Statement | |||||
| Free cash flow | — | — | -$280.7 | -$186.5 | -$19.9 |
Shares outstanding 94.3M · Free float 92.2%
Annual filing data through FY ended December 31, 2025; float as of September 29, 2026.